Key result
Genetic testing of an adoptee and her mother revealed heterozygosity for R719Q and T1513S variants in the MYH7 gene, suggesting a malignant combination imparting poor prognosis and SCD risk.
Case Report (n=2)
The combination of R719Q and T1513S variants in the MYH7 gene in cis may represent a malignant variant associated with poor prognosis and sudden cardiac death risk in hypertrophic cardiomyopathy.
May inform genetic counseling in HCM adoptees; leaves open validation of this MYH7 combination for SCD risk stratification.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease with an autosomal dominant mode of transmission. Comprehensive genetic screening of several genes frequently found mutated in HCM is recommended for first-degree relatives of HCM patients. Genetic testing provides the means to identify those at risk of developing HCM and to institute measures to prevent sudden cardiac death (SCD). Here, we present an adoptee whose natural mother and maternal relatives were known be afflicted with HCM and SCD. The proband was followed closely from age 6 to 17 years, revealing a natural history of the progression of clinical findings associated with HCM. Genetic testing of the proband and her natural mother, who is affected by HCM, revealed that they were heterozygous for both the R719Q and T1513S variants in the cardiac beta-myosin heavy chain (MYH7) gene. The proband's ominous family history indicates that the combination of the R719Q and T1513S variants in cis may be a "malignant" variant that imparts a poor prognosis in terms of the disease progression and SCD risk.
No takes yet. Share an insight, caveat, or question.
Harris et al. (2010) conducted a case report in Hypertrophic cardiomyopathy (HCM) (n=2). Genetic testing (MYH7 gene) was evaluated on Identification of genetic variants associated with HCM. Genetic testing of an adoptee and her mother revealed heterozygosity for R719Q and T1513S variants in the MYH7 gene, suggesting a malignant combination imparting poor prognosis and SCD risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: